Ligand Pharmaceuticals Incorporated (LGND)
$238.42
$2.51
(1.06%)
As on 05-Jun-2026 13:37EDT
Market cap
$4,649 Mln
Revenue (TTM)
$274 Mln
P/E Ratio
30.2
P/B Ratio
4.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
30.2
-
EV/EBITDA
19.6
-
Debt to Equity
0.4
-
Book Value
$--
-
EPS
$7.5
-
Face value
--
-
Shares outstanding
20,041,061
10 Years Aggregate
CFO
$704.40 Mln
EBITDA
$-240.05 Mln
Net Profit
$1,153.96 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
| 26.1 | 4.4 | 14.1 | 129.7 | 46.8 | 38.7 | 17.5 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
| 76.5 | 49.5 | 6.9 | -30.7 | 55.3 | -4.6 | -23.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ligand Pharmaceuticals (LGND)
|
238.4 | 4,648.7 | 274.5 | 153.6 | 76.6 | 15.8 | 30.2 | 4.7 |
| 13.8 | 4,201.5 | 3,045.9 | 122.4 | 13.8 | -- | 35.6 | 105.4 | |
| 41.0 | 5,252.7 | 1,105.3 | 133.3 | 15.9 | 32.7 | 38.3 | 12.7 | |
| 241.3 | 12,066.3 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 221.1 | |
| 68.0 | 12,977.8 | 580.0 | -725.9 | -105.2 | -- | -- | 123.7 | |
| 73.9 | 7,459.9 | 769.1 | 47.9 | 5.4 | 7.5 | 198.5 | 11.2 | |
| 13.3 | 11,337.9 | 353,471.6 | 45,087.2 | 16.1 | 12.8 | 25.6 | 2.9 | |
| 23.8 | 11,832.0 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.8 | |
| 7.6 | 5,342.5 | 7,447.6 | 415.6 | 16.2 | 6.6 | 11.1 | 0.9 | |
| 62.1 | 5,501.1 | 288.1 | 22.3 | 17.5 | 34.1 | 363.9 | 50.5 |
Shareholding Pattern
View DetailsAbout Ligand Pharmaceuticals (LGND)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA... and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. Read more
-
President & COO
Mr. Matthew E. Korenberg
-
President & COO
Mr. Matthew E. Korenberg
-
Headquarters
Jupiter, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ligand Pharmaceuticals (LGND)
What is the current share price of Ligand Pharmaceuticals Incorporated (LGND) Today?
The share price of Ligand Pharmaceuticals Incorporated (LGND) is $238.42 (NASDAQ) as of 05-Jun-2026 13:37 EDT. Ligand Pharmaceuticals Incorporated (LGND) has given a return of 46.84% in the last 3 years.
What is the current PB & PE ratio of Ligand Pharmaceuticals Incorporated (LGND)?
The P/E ratio of Ligand Pharmaceuticals Incorporated (LGND) is 30.20 times as on 29-May-2026, a 0 premium to its peers’ median range of 30.20 times.
The P/B ratio of Ligand Pharmaceuticals Incorporated (LGND) is 4.74 times as on 29-May-2026, a 20 discount to its peers’ median range of 5.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.11
|
3.93
|
|
2024
|
-504.23
|
2.45
|
|
2023
|
24.21
|
1.80
|
|
2022
|
-33.82
|
1.89
|
|
2021
|
29.19
|
2.03
|
What is the 52 Week High and Low of Ligand Pharmaceuticals Incorporated (LGND)?
The 52-week high and low of Ligand Pharmaceuticals Incorporated (LGND) are Rs 247.38 and Rs 102.50 as of 06-Jun-2026.
What is the market cap of Ligand Pharmaceuticals Incorporated (LGND)?
Ligand Pharmaceuticals Incorporated (LGND) has a market capitalisation of $ 4,649 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ligand Pharmaceuticals Incorporated (LGND)?
Before investing in Ligand Pharmaceuticals Incorporated (LGND), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.